Quantitative prediction of the extent of drug–drug interaction using a physiologically based pharmacokinetic model that includes inhibition of drug metabolism determined in cryopreserved hepatocytes

References

• Bertz RJ, Granneman GR. (1997). Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210–58
   PubMed Web of Science ®Google Scholar
• Brown HS, Chadwick A, Houston JB. (2007). Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination. Drug Metab Dispos 35:2119–26
   PubMed Web of Science ®Google Scholar
• Brown HS, Wilby AJ, Alder J, Houston JB. (2010). Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay. Drug Metab Dispos 38:2139–46
   PubMed Web of Science ®Google Scholar
• Chovan JP, Ring SC, Yu E, Baldino JP. (2007). Cytochrome P450 probe substrate metabolism kinetics in Sprague Dawley rats. Xenobiotica 37:459–73
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
   PubMed Web of Science ®Google Scholar
• DIDB: Copyright University of Washington 1999–2017. UW Metabolism and Transport Drug Interaction Database [online]. Available from: https://www.druginteractioninfo.org [Accessed 30 July, 2017]
   Google Scholar
• Einolf HJ. (2007). Comparison of different approaches to predict metabolic drug–drug interactions. Xenobiotica 37:1257–94
   PubMed Web of Science ®Google Scholar
• Eliot LA, Foster RT, Jamali F. (1999). Effects of hyperlipidemia on the pharmacokinetics of nifedipine in the rat. Pharm Res 16:309–13
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ. (2014). In vitro prediction of clinical drug interactions with CYP3A substrates: we are not there yet. Clin Pharmacol Ther 95:133–5
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Zhao Y, Venkatakrishnan K, et al. (2011). Mechanism of cytochrome P450-3A inhibition by ketoconazole. J Pharm Pharmacol 63:214–21
   PubMed Web of Science ®Google Scholar
• Guengerich FP, Martin MV, Beaune PH, et al. (1986). Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051–60
   PubMed Web of Science ®Google Scholar
• Huang SM, Strong JM, Zhang L, et al. (2008). New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662–70
   PubMed Web of Science ®Google Scholar
• Iwasaki S, Hirabayashi H, Funami M, Amano N. (2017). Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug–drug interactions in rat liver. Xenobiotica 47:488–97
   PubMed Web of Science ®Google Scholar
• Kishimoto W, Takano J, Senda C, et al. (2000). Quantitative prediction of in vivo drug interactions between nevirapine and antifungal agents from in vitro data in rats. Biol Pharm Bull 23:1027–32
   PubMed Web of Science ®Google Scholar
• Kondo S, Sugimoto I. (1987). Moment analysis of intravenous, intraduodenal, buccal, rectal and percutaneous nifedipine in rats. J Pharmacobiodyn 10:462–9
   PubMedGoogle Scholar
• Kosugi Y, Hirabayashi H, Igari T, et al. (2014). Risk assessment of drug–drug interactions using hepatocytes suspended in serum during the drug discovery process. Xenobiotica 44:336–44
   PubMed Web of Science ®Google Scholar
• Lu C, Berg C, Prakash SR, et al. (2008a). Prediction of pharmacokinetic drug–drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro–in vivo correlation with fluconazole. Drug Metab Dispos 36:1261–6
   PubMed Web of Science ®Google Scholar
• Lu C, Hatsis P, Berg C, et al. (2008b). Prediction of pharmacokinetic drug–drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro–in vivo correlation with ketoconazole. Drug Metab Dispos 36:1255–60
   PubMed Web of Science ®Google Scholar
• Lu C, Miwa GT, Prakash SR, et al. (2007). A novel model for the prediction of drug–drug interactions in humans based on in vitro cytochrome p450 phenotypic data. Drug Metab Dispos 35:79–85
   PubMed Web of Science ®Google Scholar
• Lundquist P, Loof J, Sohlenius-Sternbeck AK, et al. (2014). The impact of solute carrier (SLC) drug uptake transporter loss in human and rat cryopreserved hepatocytes on clearance predictions. Drug Metab Dispos 42:469–80
   PubMed Web of Science ®Google Scholar
• Mao J, Mohutsky MA, Harrelson JP, et al. (2011). Prediction of CYP3A-mediated drug–drug interactions using human hepatocytes suspended in human plasma. Drug Metab Dispos 39:591–602
   PubMed Web of Science ®Google Scholar
• Mao J, Mohutsky MA, Harrelson JP, et al. (2012). Predictions of cytochrome P450-mediated drug–drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions. Drug Metab Dispos 40:706–16
   PubMed Web of Science ®Google Scholar
• Niwa T, Shiraga T, Takagi A. (2005). Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 28:1805–8
   PubMed Web of Science ®Google Scholar
• Perdaems N, Blasco H, Vinson C, et al. (2010). Predictions of metabolic drug–drug interactions using physiologically based modelling: two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Clin Pharmacokinet 49:239–58
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Chu X, Gibson C, et al. (2013). Drug–drug interaction studies: regulatory guidance and an industry perspective. AAPS J 15:629–45
   PubMed Web of Science ®Google Scholar
• Rioux N, Bellavance E, Bourg S, et al. (2013). Assessment of CYP3A-mediated drug–drug interaction potential for victim drugs using an in vivo rat model. Biopharm Drug Dispos 34:396–401
   PubMed Web of Science ®Google Scholar
• Scherling D, Karl W, Radtke M, et al. (1992). Biotransformation of nifedipine in rat and dog. Arzneimittelforschung 42:1292–300
   PubMed Web of Science ®Google Scholar
• Shibata Y, Takahashi H, Chiba M, Ishii Y. (2008). A novel approach to the prediction of drug–drug interactions in humans based on the serum incubation method. Drug Metab Pharmacokinet 23:328–39
   PubMed Web of Science ®Google Scholar
• Uchida S, Tanaka S, Namiki N. (2014). Simultaneous and comprehensive in vivo analysis of cytochrome P450 activity by using a cocktail approach in rats. Biopharm Drug Dispos 35:228–36
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kusuhara H, Watanabe T, et al. (2011). Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug–drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos 39:1031–8
   PubMed Web of Science ®Google Scholar
• Yamano K, Yamamoto K, Kotaki H, et al. (1999). Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver. Drug Metab Dispos 27:395–402
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. (1981). A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4:879–85
   PubMedGoogle Scholar
• Yeo KR, Jamei M, Rostami-Hodjegan A. (2013). Predicting drug–drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Rev Clin Pharmacol 6:143–57
   PubMed Web of Science ®Google Scholar